Axel G. Glasmacher
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Challenges and Potential Solutions to Advance Global Cancer Drug Development.
Journal: Therapeutic innovation & regulatory science
Published: October 14, 2025
Corrigendum to "Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop"[Eur. J. Cancer 226 (2025), 115593].
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 11, 2025
Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 25, 2025
Central and Eastern Europe: A crucible for clinical cancer innovation?
Journal: Journal of cancer policy
Published: April 10, 2025
Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients.
Journal: Acta haematologica
Published: December 19, 2024
Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria.
Journal: European journal of haematology
Published: September 02, 2021
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Journal: European journal of haematology
Published: October 29, 2019
Bisphosphonates in multiple myeloma: a network meta-analysis.
Journal: The Cochrane database of systematic reviews
Published: May 18, 2012
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Journal: Haematologica
Published: December 03, 2011
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.
Journal: British journal of haematology
Published: February 01, 2006
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Journal: The Journal of antimicrobial chemotherapy
Published: December 13, 2005
Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients.
Journal: The Journal of antimicrobial chemotherapy
Published: November 26, 2005
Last Updated: 09/26/2026